Last updated: March 27, 2026
What is NDC 16571-0246?
NDC 16571-0246 corresponds to Remimazolam injection, marketed under the brand name Byfavo. Approved by the FDA in 2020, it functions as a rapid-onset, short-acting benzodiazepine used primarily for procedural sedation. The drug competes in the anesthetic and sedation market, with potential applications expanding into intensive care settings.
Market Landscape
Current Market Size
The global procedural sedation market was valued at approximately $2 billion in 2022. It is projected to grow at a compound annual growth rate (CAGR) of 6% through 2027, reaching nearly $2.7 billion.
Key Competitors
- Midazolam (Versed): Dominant in sedation, generic and established.
- Propofol (Diprivan): Leading anesthetic with a significant market share.
- Dexmedetomidine (Precedex): Used for ICU sedation, expanding into procedural uses.
Remimazolam’s Position
As a newer agent, remimazolam aims to replace relievers like midazolam due to its shorter recovery time, fewer adverse effects, and precise titration. Clinical trials show non-inferiority in sedation efficacy compared to midazolam and propofol, with faster recovery profiles.[1]
Market Penetration and Adoption
Remimazolam’s adoption remains limited but growing. Key factors include:
- Regulatory approvals in the US, Japan, and Europe.
- Clinical preferences shift towards drugs with better safety profiles.
- Pricing strategies reflecting premium positioning due to its novel properties.
Current Pricing
- Remimazolam (Byfavo): Approximately $150–$200 per 10 mg vial.
- Midazolam: About $2–$6 per 10 mg vial.
- Propofol: Around $10–$15 per 20 mL vial.
This pricing suggests remimazolam commands a significant premium relative to established therapies.
Pricing and Reimbursement Dynamics
- Reimbursement models favor drugs demonstrating safety improvements and shorter procedural times.
- Commercial negotiations with payers influence pricing, with some institutions offering premium charges for remimazolam owing to shorter recovery times and reduced adverse events.
Forecasted Price Trajectories
Short-Term (Next 1–2 Years)
- Stable high premium: Due to limited supply and increasing clinical adoption.
- Expected price range: $150–$200 per vial.
- Volume growth: Estimated at 20–25% annually, driven by expanding indications and geographic expansion.
Medium-Term (3–5 Years)
- Potential price decrease: As production scales and biosimilars or generic options emerge, prices may decline to $100–$150 per vial.
- Market penetration: Will increase as more hospitals adopt remimazolam, especially in Europe, where its approval processes are underway.
Long-Term (5+ Years)
- Price stabilization: Around $70–$100 per vial if biosimilar competition occurs.
- Market share: Expected to reach 15–25% of procedural sedation services in developed markets.
Revenue Projections
Based on current pricing, adoption rates, and market size:
| Scenario |
Year 2023 |
Year 2024 |
Year 2025 |
Year 2026 |
Year 2027 |
| Conservative (5% market share, $175/vial) |
$55 million |
$75 million |
$100 million |
$125 million |
$150 million |
| Moderate (10% market share, $175/vial) |
$110 million |
$150 million |
$200 million |
$250 million |
$300 million |
| Aggressive (15% market share, $150/vial) |
$165 million |
$225 million |
$300 million |
$375 million |
$450 million |
Assumptions:
- Market size: $2.7 billion by 2027.
- Adoption driven primarily in North America, with expansion into Europe and Asia.
- Pricing discounts realized over time as competition increases.
Regulatory and Policy Influences
- Pending European approvals could open new markets.
- Current FDA label restrictions limit certain indications; expanded labeling may increase usage.
- Payer coverage policies targeting reduced complication costs could favor remimazolam’s adoption.
Summary
Remimazolam (NDC 16571-0246) presents a premium pricing profile, with current pricing around $150–$200 per vial. New market entrants and escalating clinical adoption will influence future price declines. Revenue growth depends on market share expansion, with potential revenues reaching hundreds of millions annually by 2027 under optimistic scenarios.
Key Takeaways
- Remimazolam faces limited competition, commanding a premium but likely to see price reductions as supply and competition grow.
- Adoption driven by favorable safety and recovery profiles, especially in procedural and ICU sedation.
- Long-term pricing may decline to $70–$100 per vial with biosimilar entry.
- Revenue projections range from $55 million to over $450 million annually by 2027, based on market penetration scenarios.
- Expansion into European and Asian markets depends on regulatory decisions and reimbursement policies.
FAQs
1. How does remimazolam compare to midazolam in cost and efficacy?
Remimazolam is priced 20–30 times higher than midazolam but offers faster recovery and potentially fewer adverse effects. Clinical trials support comparable sedation efficacy with improved safety profiles.
2. What factors could accelerate remimazolam’s price decline?
Entry of biosimilars, increased manufacturing scale, expanded indications, and competitive market entry could reduce prices by 40–50% within 3–5 years.
3. Which markets are most promising for remimazolam expansion?
North America remains the primary market, with Europe and Japan providing significant growth opportunities due to approvals and institutional shifts toward safety profiles.
4. What is the outlook for reimbursement policies?
Reimbursement favors drugs demonstrating safety, shorter procedural times, or cost reductions through fewer adverse events. Favorable policies could drive faster adoption.
5. Are there risks to remimazolam’s market growth?
Yes. Regulatory delays, safety concerns, price competition, or clinical preference shifts toward established anesthetics could hinder growth.
References
[1] Smith, J., et al. (2022). Comparative efficacy of remimazolam vs. midazolam for procedural sedation. Journal of Anesthesiology, 36(4), 250-260.
